MENU
CHRS
AS OF
Nov 13, 04:59 PM (EDT)
Price
$1.25
Change
-$0.11 (-8.09%)
Capitalization
164.38M
124 days until earnings call
Intraday BUY SELL Signals
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2025 All rights reserved. Tickeron Inc.
CHRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Coherus Oncology (CHRS) Earnings Date & Reports

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

CHRS is expected to report earnings to rise 2.48% to -33 cents per share on March 17

Coherus Oncology CHRS Stock Earnings Reports
Q4'25
Est.
$-0.34
Q3'25
Missed
by $0.01
Q2'25
Missed
by $0.08
Q1'25
Missed
by $2.05
Q4'24
Beat
by $0.02
The last earnings report on November 06 showed earnings per share of -33 cents, missing the estimate of -31 cents. With 866.99K shares outstanding, the current market capitalization sits at 164.38M.
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
CHRS
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CHRS showed earnings on November 06, 2025. You can read more about the earnings report here.
View AI-Driven Trading for CHRS
A.I. Advisor
published General Information

General Information

a maker of biologic therapeutics for oncology and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com